6 studies found for:    Open Studies | Hemostatic Disorders | UCSD OR UC San Diego OR VA San Diego
Show Display Options
Download search resultsDownload the search results for:
Open Studies | Hemostatic Disorders | UCSD OR UC San Diego OR VA San Diego (6 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Condition: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Glasdegib (PF-04449913);   Drug: Placebo
2 Recruiting Ipilimumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Conditions: Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
3 Available Expanded Access Treatment Protocol CA204-143
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab
4 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
5 Recruiting Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Conditions: Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Intervention: Genetic: cytogenetic analysis
6 Recruiting Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018

Indicates status has not been verified in more than two years